Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BENDER, A. N.
Right arrow Articles by ENGEL, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BENDER, A. N.
Right arrow Articles by ENGEL, W. K.
NEUROLOGY 1976;26:477
© 1976 American Academy of Neurology

The acetylcholine receptor in normal and pathologic states

Immunoperoxidase visualization of alpha-bungarotoxin binding at a light and electron-microscopic level

ADAM N. BENDER, M.D., STEVEN P. RINGEL, M.D. and W. KING ENGEL, M.D.

From the Medical Neurology Branch, NINCDS, Bethesda, MD 20014.

Acetylcholine receptor now can be visualized in the muscle sarcolemmal membrane with the use of an immunoperoxidase staining of alpha-bungarotoxin ({alpha} BT), a substance that binds specifically to the acetylcholine receptor. This technique has allowed new observations in various neuromuscular diseases in which the acetylcholine receptor is affected. In normal muscle, the acetylcholine receptor is confined to the neuromuscular junction. In both experimental denervation and human denervating illnesses, the acetylcholine receptor becomes present diffusely along the muscle sarcolemmal membrane in denervated fibers. In myasthenia gravis, a circulating factor that blocks {alpha} BT binding to the acetylcholine receptor of either normal neuromuscular junctions or denervated sarcolemmal membranes is present in 68 percent of serums tested.

Dr. Ringel's present address is Department of Neurology, University of Colorado Medical Center, Denver, CO 10029.

Dr. Bender's present address is Department of Neurology, Mt. Sinai Hospital, New York, NY 10029.

This paper was presented in part at the twenty-seventh annual meeting of the American Academy of Neurology, Bal Harbour, Florida, April 1975.

Received for publication September 10, 1975.




This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
B. C. Harrison, M. L. Bell, D. L. Allen, W. C. Byrnes, and L. A. Leinwand
Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice
J Appl Physiol, January 1, 2002; 92(1): 313 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
W. K. Engel
Dagen des Oordeels: Pathokinetic Mechanisms and Molecular Messengers (A Dramatic View)
Arch Neurol, June 1, 1979; 36(6): 329 - 339.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
G. M. Fenichel
Clinical Syndromes of Myasthenia in Infancy and Childhood: A Review
Arch Neurol, February 1, 1978; 35(2): 97 - 103.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. A. Brumback, T. E. Bertorini, W. K. Engel, J. L. Trotter, K. L. Oliver, and G. C. Zirzow
The Effect of Pharmacologic Acetylcholine Receptor on Fibrillation and Myotonia in Rat Skeletal Muscle
Arch Neurol, January 1, 1978; 35(1): 8 - 10.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. P. Ringel, A. N. Bender, and W. K. Engel
Extrajunctional Acetylcholine Receptors: Alterations in Human and Experimental Neuromuscular Diseases
Arch Neurol, November 1, 1976; 33(11): 751 - 758.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.